KCSA Strategic Communications Clients Advance Psychedelic Therapies from Pre-Clinical Research to Final Stage FDA Approval as Industry Transitions to Commercial Reality

In addition to managing the media at the upcoming Psychedelic Science 2025 in Denver, KCSA curates business workshops and participates in a panel discussion on "Shaping Public Opinion: New IPSOS/MAPS Study on Public Opinion and Trust"

NEW YORK, June 10, 2025 /PRNewswire/ -- During the unprecedented 2019–2024 investment surge in psychedelic medicine, KCSA Strategic Communications' clients capitalized on market momentum to raise hundreds of millions of dollars while advancing breakthrough therapies from early-stage research to Phase III clinical trials and public market success. As companies in KCSA's portfolio achieved critical regulatory milestones and completed successful public offerings, the firm's strategic communications approach helped navigate both the sector's explosive growth period and subsequent market maturation.

KCSA's industry leadership spans client work, thought leadership and field-building initiatives. Since 2019, the firm has served as agency of record for the Multidisciplinary Association for Psychedelic Studies (MAPS) and both the Psychedelic Science 2023 and the upcoming Psychedelic Science 2025 conferences. KCSA managed media relations for more than 350 journalists at the 2023 event and continues to program and lead the business workshops for both conferences, leveraging the firm's unique expertise at the intersection of psychedelic science and capital markets.

KCSA's neuroscience and psychedelic medicine clients have achieved significant milestones, including NASDAQ listings, successful reverse takeovers, completion of pivotal clinical trials and regulatory submissions. The firm's approach has supported companies like atai Life Sciences, Delix Therapeutics, Awakn, Field Trip, Reunion Neuroscience, HMNC Brain Health, Rose Hill Life Sciences and Cybin in navigating complex stakeholder landscapes while building investor confidence and accelerating patient recruitment for critical studies. The company is also working with nonprofits in the space—such as Reason for Hope and the Veterans Mental Health Leadership Coalition—that are tirelessly broadening access to life-saving breakthrough therapies and treatments for patients, particularly our nation's veterans, by bringing together the most knowledgeable team of doctors, scientists, legal professionals, policy advocates and changemakers to advocate for sensible policies and cross-sector collaboration.

"Our client experience demonstrates that the psychedelic renaissance is not just a cultural phenomenon but a scientific and medical imperative," said Lewis Goldberg, managing partner at KCSA Strategic Communications. "During the 2019–2024 investment surge, our clients raised over $500 million in funding while advancing critical clinical programs. Our mission has been to ensure that this movement is grounded in rigorous science and guided by ethical storytelling—helping to advance therapies that hold promise for millions living with depression, PTSD and addiction."

Rick Doblin, Ph.D., founder and president of MAPS, commented: "Lewis and Anne have helped amplify the voices of the psychedelic movement with honesty, integrity and compassion. MAPS is proud to have partnered with KCSA for six years and counting, working together to communicate the science and the policies to help lay the foundation for the responsible integration of psychedelics into our society."

Ronan Levy, co-founder and former CEO of Field Trip Health & Wellness, noted, "KCSA played a critical role in laying the groundwork for Field Trip's reverse takeover (RTO) in Canada, our transition to the NASDAQ and our successful fundraising efforts. Their team's expertise helped us raise hundreds of millions of dollars in the private and public markets, enabling us to execute on our mission of transforming mental health care."

Anne Donohoe, managing director at KCSA, added, "Our work with PS2023, PS2025 and leading industry pioneers has shown us the power of communication to accelerate both scientific progress and investment. Storytelling plays a critical role in demystifying psychedelics and advancing the public understanding needed to normalize and scale breakthrough mental health treatments. By bringing these narratives to life—from patient journeys to clinical breakthroughs—we help shift perception and build the cultural foundation these therapies need to thrive."

As the psychedelic medicine field transitions from experimental research to commercial reality, KCSA Strategic Communications continues to partner with innovative neuroscience companies navigating complex regulatory landscapes, investment challenges and market development opportunities. The firm's decade-long track record in translating complex science into compelling narratives positions it as a strategic partner for companies advancing novel therapeutics from laboratory to patient care.

About KCSA Strategic Communications

KCSA is an award-winning strategic communications firm that specializes in public relations, investor relations and integrated marketing. With decades of experience in healthcare, life sciences and emerging industries, KCSA is dedicated to translating complex science into accessible, actionable messaging that builds trust and drives progress. Since 1969, KCSA has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The Firm's clients are its best references. For more information, please visit www.kcsa.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kcsa-strategic-communications-clients-advance-psychedelic-therapies-from-pre-clinical-research-to-final-stage-fda-approval-as-industry-transitions-to-commercial-reality-302477316.html

SOURCE KCSA Strategic Communications